Explore our news bulletins and archive
for the latest press coverage, as well as articles of interest.

H&S reaches settlement on behalf of Solodyn purchasers

April 5, 2018 - A Massachusetts federal judge gave her initial approval Thursday to Impax Laboratories Inc.’s $20 million mid-trial settlement with a class of consumers and insurers. 

The suit claimed that Impax unlawfully delayed the launch of its generic acne medicine for three years in exchange for a $40 million payment from Medicis Pharmaceutical Corp., the maker of Solodyn. 

Judge Casper said the settlement “was concluded after arm’s-length negotiations by experienced counsel on behalf of the certified end-payor class.”

The settlement with Impax marks the conclusion of the case. Before trial, the “end-payor” class reached settlements with the other defendants totaling $23 million.